Walid Macaron

Walid Macaron

Auto-generated profile, based on publicly available information

Walid Macaron

Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
HKHagop Kantarjian
Hagop Kantarjian
FRFarhad Ravandi
Farhad Ravandi
MKMarina Konopleva
Marina Konopleva
NJNitin Jain
Nitin Jain
EJElias Jabbour
Elias Jabbour
Measurable residual disease (MRD) is highly prognostic for relapse and overall survival (OS) in acute lymphoblastic leukemia (ALL), although many patients with apparent “MRD negativity” by standard assays still relapse. We evaluated the clinical impact of a highly sensitive next-generation sequencing (NGS) MRD assay in 74 adults with ALL undergoing frontline therapy. Among remission samples that were MRD negative by multiparameter flow cytometry (MFC), 46% were MRD+ by the NGS assay. After 1 cycle of induction chemotherapy, MRD negativity by MFC at a sensitivity of 1 × 10−4 and NGS at a sensitivity of 1 × 10−6 was achieved in 66% and 23% of patients, respectively. The 5-year cumulative incidence of relapse (CIR) among patients who achieved MRD negativity by MFC at complete remission (CR) was 29%; in contrast, no patients who achieved early MRD negativity by NGS relapsed, and their 5-year OS was 90%. NGS MRD negativity at CR was associated with significantly decreased risk of relapse compared with MRD positivity (5-year CIR, 0% vs 45%, respectively; P = .04). Among patients who were MRD negative by MFC, detection of low levels of MRD by NGS identified patients who still had a significant risk of relapse (5-year CIR, 39%). Early assessment of MRD using a highly sensitive NGS assay adds clinically relevant prognostic information to standard MFC-based approaches and can identify patients with ALL undergoing frontline therapy who have a very low risk of relapse and excellent long-term survival.

15 May 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
EJElias Jabbour
Elias Jabbour
WMWalid Macaron
Walid Macaron
Farhad RavandiFarhad Ravandi
Farhad Ravandi
Nitin JainNitin Jain
Nitin Jain
HKHagop Kantarjian
Hagop Kantarjian

31 March 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
WMWalid Macaron
Walid Macaron
ZSZaven Sargsyan
Zaven Sargsyan
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
Leukostasis is a life-threatening complication of high concentrations of circulating leukemic cells, most often myeloblasts. Effective care of patients with leukostasis involves early recognition and treatment, and aggressive management of concurrent complications of the underlying leukemia. The relatively poor prognosis in patients with leukostasis underscores the importance of the timely and effective care of this hematologic emergency. While cytoreductive measures such as hydroxyurea, corticosteroids, intravenous chemotherapy, and leukapheresis are available to urgently reduce high cell counts, characterization of the leukemia and initiation of tailored, definitive treatment is a parallel priority. However, data supporting any specific cytoreductive approach are limited, making clinical practice guided primarily by expert opinion. In this review, we discuss the pathophysiology, clinical manifestations, diagnosis, and management of leukemic hyperleukocytosis and leukostasis, with an emphasis on how to acutely manage this oncologic emergency in patients with acute myeloid leukemia, which is the most common cause of symptomatic leukostasis.

4 July 2024 in Blood
Verified
Journal Article
Closed access
PDF file
YZYaqi Zhao
Yaqi Zhao
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
HKHagop M. Kantarjian
Hagop M. Kantarjian
TCTi-Cheng Chang
Ti-Cheng Chang
PGPankaj S. Ghate
Pankaj S. Ghate
CMCharles G Mullighan
Charles G Mullighan
Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO–treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing. Acquired CD22 mutations were observed in 11% (3/27) of post-InO-relapsed tumor samples, but not in refractory samples (0/16). There were multiple CD22 mutations per sample and the mechanisms of CD22 escape included epitope loss (protein truncation and destabilization) and epitope alteration. Two CD22 mutant cases were post-InO hyper-mutators resulting from error-prone DNA damage repair (nonhomologous/alternative end-joining repair, or mismatch repair deficiency), suggesting that hypermutation drove escape from CD22-directed therapy. CD22-mutant relapses occurred after InO and subsequent hematopoietic stem cell transplantation (HSCT), suggesting that InO eliminated the predominant clones, leaving subclones with acquired CD22 mutations that conferred resistance to InO and subsequently expanded. Acquired loss-of-function mutations in TP53, ATM, and CDKN2A were observed, consistent with a compromise of the G1/S DNA damage checkpoint as a mechanism for evading InO-induced apoptosis. Genome-wide CRISPR/Cas9 screening of cell lines identified DNTT (terminal deoxynucleotidyl transferase) loss as a marker of InO resistance. In conclusion, genetic alterations modulating CD22 expression and DNA damage response influence InO efficacy. Our findings highlight the importance of defining the basis of CD22 escape and eradication of residual disease before HSCT. The identified mechanisms of escape from CD22-targeted therapy extend beyond antigen loss and provide opportunities to improve therapeutic approaches and overcome resistance. These trials were registered at www.ClinicalTrials.gov as NCT01134575, NCT01371630, and NCT03441061.

20 April 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
GBGautam Borthakur
Gautam Borthakur
NPNaveen Pemmaraju
Naveen Pemmaraju
CDCourtney D. Dinardo
Courtney D. Dinardo
TKTapan M. Kadia
Tapan M. Kadia
Naval DaverNaval Daver
Naval Daver
We conducted a phase Ib/II multi-arm, parallel cohort study to simultaneously evaluate various immunotherapeutic agents and combinations in relapsed/refractory acute myeloid leukemia (AML). Overall, 50 patients were enrolled into one of 6 arms: (A) single agent PF-04518600 (OX40 agonist monoclonal antibody), (B) azacitidine + venetoclax + gemtuzumab ozogamicin (GO), (C) azacitidine + avelumab (anti-PD-L1 monoclonal antibody) + GO, (D) azacitidine + venetoclax + avelumab, (E) azacitidine + avelumab + PF-04518600, and (F) glasdegib + GO. Among all regimens evaluated, azacitidine + venetoclax + GO appeared most promising. In this arm, the CR/CRi rates among venetoclax-naïve and prior venetoclax-exposed patients were 50% and 22%, respectively, and the 1-year OS rate was 31%. This study shows the feasibility of a conducting a multi-arm trial to efficiently and simultaneously evaluate novel therapies in AML, a needed strategy in light of the plethora of emerging therapies. This trial was registered at www.clinicaltrials.gov as NCT03390296.

26 September 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
SVSangeetha Venugopal
Sangeetha Venugopal
CDCourtney Dinardo
Courtney Dinardo
SLSanam Loghavi
Sanam Loghavi
WQWei Qiao
Wei Qiao
Farhad RavandiFarhad Ravandi
Farhad Ravandi
Nicholas J. ShortNicholas J. Short
Nicholas J. Short